Physician profile
Deborah Nicholson
NPI 1063576049
$7,967.75
in general payments reported to CMS, 2019-2025
23 companies · $1,840 in 2025
The $1,840 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2020: $423 · 2021: $1,145 · 2022: $1,320 · 2023: $1,380 · 2024: $1,398 · 2025: $1,840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,604 · Education: $14.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,603.80 |
| Education | $14.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,681.41 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,399.71 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,264.38 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $916.20 | 2019-2025 | Nucala, Trelegy Ellipta |
| Optinose US, INC. | $640.55 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $412.06 | 2019-2022 | |
| Genentech USA, INC. | $330.20 | 2019-2025 | Xolair |
| Amgen INC. | $289.22 | 2021-2024 | Tezspire |
| Pfizer INC. | $208.21 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $202.07 | 2023-2025 | |
| Lilly USA, LLC | $156.52 | 2024-2025 | Taltz, Ebglyss |
| Teva Pharmaceuticals USA, INC. | $139.63 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $57.01 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $49.83 | 2025 | Neffy |
| Janssen Biotech, INC. | $45.33 | 2025 | Tremfya |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $44.54 | 2025 | Xhance |
| Incyte Corporation | $26.31 | 2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $24.70 | 2020 | |
| Organon LLC | $19.51 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $18.41 | 2025 | Nemluvio |
| Merck Sharp & Dohme LLC | $17.67 | 2021 | |
| Kaleo, INC. | $13.10 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Nicholson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.